| __timestamp | Insmed Incorporated | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 31073000 | 612613000000 |
| Thursday, January 1, 2015 | 43216000 | 650773000000 |
| Friday, January 1, 2016 | 50679000 | 619061000000 |
| Sunday, January 1, 2017 | 79171000 | 628106000000 |
| Monday, January 1, 2018 | 168218000 | 717599000000 |
| Tuesday, January 1, 2019 | 210796000 | 964737000000 |
| Wednesday, January 1, 2020 | 203613000 | 875663000000 |
| Friday, January 1, 2021 | 234273000 | 886361000000 |
| Saturday, January 1, 2022 | 265784000 | 997309000000 |
| Sunday, January 1, 2023 | 344501000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
In pursuit of knowledge
In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Takeda Pharmaceutical Company Limited and Insmed Incorporated have shown contrasting trends in their SG&A expenses. From 2014 to 2023, Takeda's expenses have consistently been over 3,000 times higher than Insmed's, reflecting its larger scale and global reach. Notably, Takeda's SG&A expenses peaked in 2023, reaching over 1 trillion yen, a 72% increase from 2014. Meanwhile, Insmed's expenses have grown more than tenfold, from 31 million in 2014 to 345 million in 2023, indicating its aggressive expansion strategy. However, data for 2024 is incomplete, highlighting the need for continuous monitoring. This comparison underscores the diverse strategies and challenges faced by pharmaceutical companies in managing operational costs.
Comparing SG&A Expenses: Novartis AG vs Insmed Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited vs Insmed Incorporated: Efficiency in Cost of Revenue Explored
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
Breaking Down SG&A Expenses: Insmed Incorporated vs Sarepta Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Amneal Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Insmed Incorporated and Vericel Corporation
Who Optimizes SG&A Costs Better? Insmed Incorporated or Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Iovance Biotherapeutics, Inc.